ANDERS HOVE, M.D. - Corporate Board Profile

Oruka Therapeutics, Inc.

Filing Date	Source Excerpt
2017-04-21	Dr. Hove, age 51, has served as a member of the Board of Directors since February 2017. ... Upon his appointment to our Board of Directors in February 2017, Dr. Hove joined our Nominating and Corporate Governance Committee. ... Dr. Hove is not included in the table above because he did not serve as a director in the fiscal year ended December 31, 2016.
2018-04-18	Dr. Hove, age 52, has served as a member of the Board of Directors since February 2017. Dr. Hove owns Acorn Capital Advisors and is a managing partner at Majalin/Amzak Health, a partnership focusing on long-term investments in biotech, specialty pharma and medical device companies. Dr. Hove was most recently a general partner of Venrock Associates, a venture capital firm, which he joined in January 2004 and remained at through December 2016. In 2008, Dr. Hove was a founder of Venrock Healthcare Capital Partners, Venrock’s public funds focused on small capitalization biotech companies and late-stage private companies. From 1996 to 2004, Dr. Hove was a fund manager at BB Biotech Fund, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, LLC, an investment company. Dr. Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba-Geigy. Mr. Hove was a member of the boards of directors of Anacor Pharmaceuticals, a publicly traded pharmaceutical company, from 2005 until its acquisition by Pfizer in June 2016, and Edge Therapeutics, a publicly traded biotechnology company, from 2015 to 2016. In addition, Dr. Hove is a member of the board of directors of MC2 Therapeutics. He received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from the Institut Européen d’Administration des Affaires. We believe Dr. Hove is an appropriate member of the Company’s Board of Directors, given his extensive training and experience as a medical doctor and masters of business administration, an executive in the pharmaceutical industry, and as an investor in biotechnology companies. Director Compensation For fiscal year ended December 31, 2017, Dr. Hove received $40,000 in fees earned or paid in cash and $15,114 in option awards, totaling $55,114.
2018-09-20	The following table sets forth certain information regarding the ownership of the Companys Common Stock as of the August 31, 2018, by: (i) each director and nominee for director, (ii) each of our named executive officers, (iii) all executive officers and directors of the Company as a group, and (iv) all those known by the Company to be beneficial owners of more than five percent of its Common Stock.
2019-10-25	Dr. Hove, age 53, has served as a member of the Board of Directors since February 2017. ... The Audit Committee ... is composed of three directors: Mr. Conway (chair), Mr. Mitchell and Dr. Grais. ... The Nominating and Corporate Governance Committee is composed of three directors: Dr. Hove, Mr. Mitchell and Dr. Woosley (chair). ... Director Compensation for Fiscal 2018 ... Anders Hove ... $44,640.
2020-10-28	Anders Hove, M.D. Dr. Hove, age 54, has served as a member of the Board of Directors since February 2017. ... The Nominating and Corporate Governance Committee is composed of three directors: Dr. Hove, Mr. Mitchell and Dr. Woosley (chair). ... Director Compensation for Fiscal 2019 shows Dr. Hove received $40,000 in cash fees.
2021-04-21	Dr. Hove, age 55, has served as a member of the Board of Directors since February 2017. ... We believe Dr. Hove is an appropriate member of the Company’s Board of Directors, given his extensive training and experience as a medical doctor and masters of business administration, an executive in the pharmaceutical industry, and as an investor in biotechnology companies. ... The Nominating and Corporate Governance Committee is composed of three directors: Dr. Hove, Mr. Mitchell and Dr. Woosley (chair). ... Director Compensation for Fiscal 2020 ... Anders Hove ... $40,000 ...
2022-11-03	Dr. Hove, age 56, has served as a member of the Board of Directors since February 2017. ... Dr. Hove is a member of the board of directors of MC2 Therapeutics. ... The Audit Committee was composed of three directors: Mr. Conway (chair), Mr. Mitchell and Dr. Grais. ... The Nominating and Corporate Governance Committee of the Board of Directors, or the Nominating and Corporate Governance Committee, is composed of three directors: Dr. Hove, Mr. Mitchell and Dr. Woosley (chair). ... In 2022, the Board of Directors established a Special Committee ... The Special Committee includes ... Anders Hove, M.D. ... Director Compensation for Fiscal 2021 ... Anders Hove ... Fees Earned or Paid in Cash ($) 43,750 ... Option Awards ($) 39,187 ... Total ($) 82,937.
2023-12-19	Dr. Hove, age 57, has served as a member of the Board of Directors since February 2017. ... He serves on the Audit Committee, Special Committee and is Chair of the Nominating and Corporate Governance Committee. Director compensation for 2022 was $56,336.